[{"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-001", "question": "A 71-year-old woman with a dual-chamber pacemaker (DDDR) for sick sinus syndrome presents with episodic dizziness and syncope. Device interrogation reveals normal lead parameters but frequent pacemaker-mediated tachycardia (PMT) episodes terminated by the device's algorithm. However, she continues to report symptoms. Telemetry shows intermittent 2:1 AV block during atrial tracking, with every second P wave falling within post-ventricular atrial refractory period (PVARP). Which programming adjustment will most effectively eliminate symptoms while preserving maximal atrioventricular synchrony?", "options": ["Extend PVARP by 50 ms", "Enable dynamic PVARP extension after premature ventricular contractions", "Reduce upper tracking limit to 120 bpm", "Switch to DDI mode at rest", "Enable atrial preference pacing"], "answer": "B", "answer_index": 1, "explanation": "Dynamic PVARP extension after PVCs prevents retrograde conduction from initiating PMT while preserving atrial tracking during sinus rhythm. Extending PVARP statically (A) would worsen 2:1 block and cause pacemaker syndrome. Reducing upper tracking (C) does not prevent PMT initiation. DDI mode (D) eliminates atrial tracking entirely. Atrial preference pacing (E) is irrelevant to PMT prevention.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: Underspecified (U). The stem describes a DDDR pacemaker with 2:1 AV block due to every second P wave falling within PVARP, causing symptoms. The ideal fix is to shorten PVARP (or adjust atrial tracking) to restore 1:1 tracking, but this option is absent. The keyed answer (B) enables dynamic PVARP extension after PVCs, which prevents PMT triggered by PVCs but does not address the 2:1 block and may even lengthen PVARP after ectopic beats, potentially worsening the block. None of the other choices (extend PVARP, lower upper tracking limit, DDI mode, atrial preference pacing) correct the 2:1 block while preserving AV synchrony. Thus no listed option is defensible as the best answer; the item is underspecified. Medical accuracy: The explanation correctly describes the role of dynamic PVARP after PVCs, but the scenario does not mention PVCs, making the answer irrelevant. The core pathophysiology (2:1 block from overly long PVARP) is accurate, but the recommended programming is not. Score: 2 (inaccurate because the keyed answer does not solve the problem). Logical validity: false (U). Minimal fix: Replace option B with \\\"Shorten PVARP by 30–50 ms\\\" and set that as the key.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: Underspecified (U). The stem describes a DDDR pacemaker with 2:1 AV block due to every second P wave falling within PVARP, causing symptoms. The ideal fix is to shorten PVARP (or adjust atrial tracking) to restore 1:1 tracking, but this option is absent. The keyed answer (B) enables dynamic PVARP extension after PVCs, which prevents PMT triggered by PVCs but does not address the 2:1 block and may even lengthen PVARP after ectopic beats, potentially worsening the block. None of the other choices (extend PVARP, lower upper tracking limit, DDI mode, atrial preference pacing) correct the 2:1 block while preserving AV synchrony. Thus no listed option is defensible as the best answer; the item is underspecified. Medical accuracy: The explanation correctly describes the role of dynamic PVARP after PVCs, but the scenario does not mention PVCs, making the answer irrelevant. The core pathophysiology (2:1 block from overly long PVARP) is accurate, but the recommended programming is not. Score: 2 (inaccurate because the keyed answer does not solve the problem). Logical validity: false (U). Minimal fix: Replace option B with \"Shorten PVARP by 30–50 ms\" and set that as the key.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-002", "question": "A 42-year-old man with a heterozygous CSF1R p.Arg782His mutation and early-stage adult-onset leukoencephalopathy with axonal spheroids (ALSP) has mild cognitive impairment and gait instability. His sister progressed to severe dementia within 3 years of symptom onset. Which intervention has demonstrated the highest disease-modifying efficacy when performed before onset of severe motor disability?", "options": ["Intravenous immunoglobulin monthly", "Oral cyclophosphamide 2 mg/kg/day", "Allogeneic hematopoietic stem cell transplantation from HLA-matched sibling donor", "Ruxolitinib 20 mg twice daily", "Supportive care with donepezil"], "answer": "C", "answer_index": 2, "explanation": "Allogeneic HSCT is the only intervention shown to halt ALSP progression when performed early, before severe disability, by replacing microglial precursors. IVIG (A) and cyclophosphamide (B) lack efficacy. Ruxolitinib (D) has no clinical data. Supportive care (E) does not modify disease course. Delay until severe motor impairment predicts transplant failure.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V. Verdict: Correct best answer. The question seeks the disease-modifying therapy for early-stage ALSP (CSF1R-related microgliopathy) before severe motor disability. Discriminating clues: confirmed heterozygous CSF1R mutation, mild cognitive/gait impairment, and family history of rapid progression, indicating need for early intervention. Allogeneic HSCT is the only option with published evidence—case series demonstrate microglial precursor replacement can stabilize disease if performed before advanced disability. Alternatives are clearly inferior: IVIG and cyclophosphamide lack mechanistic rationale or data; ruxolitinib is preclinical; supportive care is non-modifying. Medical accuracy concern: the stem frames HSCT as having demonstrated highest efficacy, which overstates limited, non-randomized evidence and lacks guideline endorsement, potentially misrepresenting standard of care. Logical structure is valid: a single best answer exists among the options. Minimal fix: qualify HSCT as investigational, supported by case series in the stem or rationale.\",\"medical_accuracy_score\":  \"3\",\"logical_validity\": true,\"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V. Verdict: Correct best answer. The question seeks the disease-modifying therapy for early-stage ALSP (CSF1R-related microgliopathy) before severe motor disability. Discriminating clues: confirmed heterozygous CSF1R mutation, mild cognitive/gait impairment, and family history of rapid progression, indicating need for early intervention. Allogeneic HSCT is the only option with published evidence—case series demonstrate microglial precursor replacement can stabilize disease if performed before advanced disability. Alternatives are clearly inferior: IVIG and cyclophosphamide lack mechanistic rationale or data; ruxolitinib is preclinical; supportive care is non-modifying. Medical accuracy concern: the stem frames HSCT as having demonstrated highest efficacy, which overstates limited, non-randomized evidence and lacks guideline endorsement, potentially misrepresenting standard of care. Logical structure is valid: a single best answer exists among the options. Minimal fix: qualify HSCT as investigational, supported by case series in the stem or rationale.", "medical_accuracy_score": 3, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-003", "question": "A 64-year-old man with metastatic hemangiopericytoma presents with refractory hypoglycemia (glucose 28 mg/dL) despite 20% dextrose infusion at 100 mL/hour. Labs show insulin <2 μIU/mL, C-peptide 0.1 ng/mL, IGF-2 850 ng/mL (normal 50-200), and IGF-2:IGF-1 ratio 12:1. Which immediate pharmacologic intervention is most likely to achieve euglycemia within 24 hours?", "options": ["Continuous hydrocortisone infusion 10 mg/hour", "Recombinant IGF-1 40 mg subcutaneously twice daily", "Diazoxide 300 mg orally three times daily", "Octreotide 200 μg subcutaneously three times daily", "Glucagon 2 mg intramuscularly every 4 hours"], "answer": "A", "answer_index": 0, "explanation": "High-dose glucocorticoids suppress aberrant IGF-2 production from the tumor, correcting hypoglycemia within hours. Recombinant IGF-1 (B) worsens the IGF-2:IGF-1 imbalance. Diazoxide (C) and octreotide (D) are ineffective in non-islet cell tumor hypoglycemia due to suppressed insulin. Glucagon (E) provides only transient effect and cannot sustain normoglycemia.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V (Valid). Verdict: Correct best answer. Key stem clues: Metastatic hemangiopericytoma, refractory hypoglycemia despite dextrose infusion, suppressed insulin and C-peptide, markedly elevated IGF-2 and IGF-2:IGF-1 ratio >10:1, consistent with non-islet cell tumor hypoglycemia (NICTH). The question asks for the immediate pharmacologic intervention most likely to achieve euglycemia within 24 h. Among the options, high-dose glucocorticoids (hydrocortisone infusion) are the standard first-line therapy to suppress tumor IGF-2 production and improve glucose levels, typically within hours to a day. Recombinant IGF‑1 would increase the IGF‑1 pool but does not acutely reverse hypoglycemia and may worsen the IGF‑2/IGF‑1 imbalance; diazoxide and octreotide target insulin secretion, which is already suppressed; glucagon provides only transient glycemic elevation. Therefore, option A is uniquely defensible. No internal contradictions or missing data preclude a single best answer. Minor issue: the explanation overstates the speed of glucocorticoid effect, but this does not invalidate the answer. Minimal fix: revise the explanation to note that glucocorticoids begin to lower IGF‑2 within 12–24 h and that euglycemia may require 24–48 h.\",\"logical_false_reason\":\"T\",\"logical_validity\":true,\"medical_accuracy_score\":\"5\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V (Valid). Verdict: Correct best answer. Key stem clues: Metastatic hemangiopericytoma, refractory hypoglycemia despite dextrose infusion, suppressed insulin and C-peptide, markedly elevated IGF-2 and IGF-2:IGF-1 ratio >10:1, consistent with non-islet cell tumor hypoglycemia (NICTH). The question asks for the immediate pharmacologic intervention most likely to achieve euglycemia within 24 h. Among the options, high-dose glucocorticoids (hydrocortisone infusion) are the standard first-line therapy to suppress tumor IGF-2 production and improve glucose levels, typically within hours to a day. Recombinant IGF‑1 would increase the IGF‑1 pool but does not acutely reverse hypoglycemia and may worsen the IGF‑2/IGF‑1 imbalance; diazoxide and octreotide target insulin secretion, which is already suppressed; glucagon provides only transient glycemic elevation. Therefore, option A is uniquely defensible. No internal contradictions or missing data preclude a single best answer. Minor issue: the explanation overstates the speed of glucocorticoid effect, but this does not invalidate the answer. Minimal fix: revise the explanation to note that glucocorticoids begin to lower IGF‑2 within 12–24 h and that euglycemia may require 24–48 h.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-004", "question": "A 59-year-old woman with rheumatoid arthritis on methotrexate develops progressive dyspnea and weight loss. HRCT demonstrates upper lobe-predominant pleural thickening, subpleural consolidation, and traction bronchiectasis with severe volume loss. Surgical lung biopsy shows dense subpleural fibrosis with prominent elastic fiber deposition and minimal inflammation, extending into the pleura. Which histopathologic finding most strongly differentiates this from usual interstitial pneumonia?", "options": ["Fibroblast foci within alveolar walls", "Honeycomb change with mucin-filled cysts", "Presence of intra-alveolar fibroblastic plugs", "Elastosis involving visceral pleura and subpleural parenchyma", "Patchy temporally heterogeneous fibrosis"], "answer": "D", "answer_index": 3, "explanation": "Pleuroparenchymal fibroelastosis (PPFE) is defined by characteristic elastosis of both pleura and subpleural parenchyma, which is absent in UIP. Fibroblast foci (A) and honeycomb change (B) are hallmark UIP features. Intra-alveolar fibroblastic plugs (C) suggest organizing pneumonia. Patchy heterogeneous fibrosis (E) is typical of UIP, whereas PPFE shows uniform elastotic fibrosis.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V. Verdict: Correct best answer. The stem describes classic pleuroparenchymal fibroelastosis (PPFE): upper lobe-predominant pleural thickening, subpleural consolidation, traction bronchiectasis with severe volume loss, and surgical lung biopsy showing dense subpleural fibrosis with prominent elastic fiber deposition extending into the pleura. The question asks for the histopathologic finding that most strongly differentiates PPFE from usual interstitial pneumonia (UIP). The key discriminating clue is the prominent elastic fiber deposition (elastosis) involving both visceral pleura and subpleural parenchyma—a defining feature of PPFE that is absent in UIP. Option D directly captures this pathognomonic finding. Options A, B, and E describe hallmark UIP features (fibroblast foci, honeycomb change, patchy temporally heterogeneous fibrosis) and thus cannot differentiate PPFE from UIP. Option C characterizes organizing pneumonia. All options are distinct and permit clear discrimination. The keyed answer D is explicitly supported by stem details and aligns with current ATS/ERS consensus and radiology-pathology correlation standards for PPFE. No internal contradictions or missing critical details. Medical content is accurate, precise, realistic, and board-relevant. No fix required.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V. Verdict: Correct best answer. The stem describes classic pleuroparenchymal fibroelastosis (PPFE): upper lobe-predominant pleural thickening, subpleural consolidation, traction bronchiectasis with severe volume loss, and surgical lung biopsy showing dense subpleural fibrosis with prominent elastic fiber deposition extending into the pleura. The question asks for the histopathologic finding that most strongly differentiates PPFE from usual interstitial pneumonia (UIP). The key discriminating clue is the prominent elastic fiber deposition (elastosis) involving both visceral pleura and subpleural parenchyma—a defining feature of PPFE that is absent in UIP. Option D directly captures this pathognomonic finding. Options A, B, and E describe hallmark UIP features (fibroblast foci, honeycomb change, patchy temporally heterogeneous fibrosis) and thus cannot differentiate PPFE from UIP. Option C characterizes organizing pneumonia. All options are distinct and permit clear discrimination. The keyed answer D is explicitly supported by stem details and aligns with current ATS/ERS consensus and radiology-pathology correlation standards for PPFE. No internal contradictions or missing critical details. Medical content is accurate, precise, realistic, and board-relevant. No fix required.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-005", "question": "A 26-year-old woman ingests 60 mg of colchicine in a suicide attempt, presenting 8 hours later with profuse vomiting and diarrhea. Labs: WBC 22,000/μL, platelets 600,000/μL. Which intervention, when initiated within 12 hours of ingestion, has demonstrated mortality reduction in severe colchicine poisoning?", "options": ["Colchicine-specific Fab fragments 4 g IV bolus", "Granulocyte colony-stimulating factor 5 μg/kg/day subcutaneously", "Continuous venovenous hemofiltration at 50 mL/kg/hour", "N-acetylcysteine 150 mg/kg IV loading dose", "Plasma exchange daily for 5 days"], "answer": "B", "answer_index": 1, "explanation": "Early G-CSF administration reduces mortality by preventing septic complications from bone marrow suppression that begins 24-48 hours post-ingestion. Colchicine Fab (A) is experimental and unavailable. CVVH (C) does not enhance colchicine clearance due to large volume of distribution. NAC (D) has no role. Plasma exchange (E) is ineffective for intracellular toxins.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V. Verdict: Correct best answer among options, but medically questionable premise. Key stem clues driving selection: massive ingestion (60 mg), 8-hour presentation, and specific query for mortality-reducing intervention within 12 hours. No alternative is plausible—colchicine Fab (A) is experimental/unavailable, CVVH (C) ineffective due to large volume of distribution, NAC (D) has no role, and plasma exchange (E) fails for intracellular toxins. Main logical issue: None; the item permits a single best answer without internal contradiction. Main medical accuracy issue: The claim that G-CSF has 'demonstrated mortality reduction' is unsupported by robust evidence; it is not standard early therapy and misleads learners about proven mortality benefit. Minimal fix: Revise stem to ask about 'supportive care measure to address anticipated bone marrow suppression' rather than 'demonstrated mortality reduction.'\",\"medical_accuracy_score\":\"2\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V. Verdict: Correct best answer among options, but medically questionable premise. Key stem clues driving selection: massive ingestion (60 mg), 8-hour presentation, and specific query for mortality-reducing intervention within 12 hours. No alternative is plausible—colchicine Fab (A) is experimental/unavailable, CVVH (C) ineffective due to large volume of distribution, NAC (D) has no role, and plasma exchange (E) fails for intracellular toxins. Main logical issue: None; the item permits a single best answer without internal contradiction. Main medical accuracy issue: The claim that G-CSF has 'demonstrated mortality reduction' is unsupported by robust evidence; it is not standard early therapy and misleads learners about proven mortality benefit. Minimal fix: Revise stem to ask about 'supportive care measure to address anticipated bone marrow suppression' rather than 'demonstrated mortality reduction.'", "medical_accuracy_score": 2, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-006", "question": "A 55-year-old man with severe Barlow's disease undergoes 3D transesophageal echocardiography for mitral valve repair planning. The surgeon asks you to identify the parameter that best predicts durable repair. Which measurement most strongly correlates with successful leaflet coaptation after annuloplasty?", "options": ["Anterior leaflet length >35 mm", "Posterior leaflet thickness >5 mm", "Annular height to commissural width ratio >0.3", "Flail gap distance <10 mm", "Coaptation depth >15 mm"], "answer": "C", "answer_index": 2, "explanation": "Annular height to commissural width ratio >0.3 indicates adequate leaflet tissue and annular dynamics, predicting successful repair. Excessive leaflet length (A) and thickness (B) increase complexity but do not predict success. Flail gap (D) and coaptation depth (E) are important but secondary to annular geometry in Barlow's disease where tissue redundancy is the primary pathology.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\":Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. Key stem clues: 55-year-old man, severe Barlow's disease (myxomatous degeneration with redundant leaflets), 3D TEE for repair planning, surgeon asks for parameter predicting durable repair, specifically \\\"successful leaflet coaptation after annuloplasty.\\\" The question conflates two concepts: (1) predicting durable repair success and (2) successful leaflet coaptation. In Barlow's disease, multiple parameters matter: adequate tissue (annular height to commissural width ratio), but also flail gap <10 mm and coaptation depth <10 mm (not >15 mm) are established predictors. The stem does not specify whether \\\"successful coaptation\\\" means immediate technical result or long-term durability. Option C (annular height to commissural width ratio >0.3) is a validated predictor of repair feasibility, but Option D (flail gap <10 mm) is also a strong, independent predictor of successful coaptation and durability. Option E is mis-specified (coaptation depth >15 mm is abnormal; normal is <10 mm). The item is underspecified because it does not clarify whether the surgeon is asking about annular geometry versus leaflet coaptation metrics, allowing two defensible answers (C and D). The keyed answer C is partially correct but not uniquely best. Medical accuracy: The explanation contains an error—coaptation depth >15 mm is pathologic, not predictive of success. Score reflects outdated/confusing parameter. Fix: Replace Option E with \\\"Coaptation depth <10 mm\\\" and clarify whether the question asks about annular geometry or coaptation parameters specifically.\",\"logical_false_reason\":\"U\",\"logical_validity\":false,\"medical_accuracy_score\":\"3\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": ":Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. Key stem clues: 55-year-old man, severe Barlow's disease (myxomatous degeneration with redundant leaflets), 3D TEE for repair planning, surgeon asks for parameter predicting durable repair, specifically \"successful leaflet coaptation after annuloplasty.\" The question conflates two concepts: (1) predicting durable repair success and (2) successful leaflet coaptation. In Barlow's disease, multiple parameters matter: adequate tissue (annular height to commissural width ratio), but also flail gap <10 mm and coaptation depth <10 mm (not >15 mm) are established predictors. The stem does not specify whether \"successful coaptation\" means immediate technical result or long-term durability. Option C (annular height to commissural width ratio >0.3) is a validated predictor of repair feasibility, but Option D (flail gap <10 mm) is also a strong, independent predictor of successful coaptation and durability. Option E is mis-specified (coaptation depth >15 mm is abnormal; normal is <10 mm). The item is underspecified because it does not clarify whether the surgeon is asking about annular geometry versus leaflet coaptation metrics, allowing two defensible answers (C and D). The keyed answer C is partially correct but not uniquely best. Medical accuracy: The explanation contains an error—coaptation depth >15 mm is pathologic, not predictive of success. Score reflects outdated/confusing parameter. Fix: Replace Option E with \"Coaptation depth <10 mm\" and clarify whether the question asks about annular geometry or coaptation parameters specifically.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-007", "question": "A 67-year-old man presents with 18 months of progressive insomnia, dysautonomia, bulbar dysfunction, and gait instability. Polysomnography shows severe sleep fragmentation with complete loss of REM sleep. Anti-IgLON5 antibodies are positive in serum and CSF. Which therapeutic strategy has demonstrated modest symptomatic benefit in this tauopathy-mediated autoimmune disorder?", "options": ["High-dose intravenous methylprednisolone 1 g daily for 5 days", "Plasma exchange every other day for 2 weeks", "Rituximab 1 g IV every 2 weeks for 2 doses", "Combined immunotherapy with steroids, IVIG, and rituximab", "Trazodone 100 mg nightly for sleep restoration"], "answer": "D", "answer_index": 3, "explanation": "Combined immunotherapy offers modest benefit in IgLON5 disease by targeting both autoimmune and inflammatory components, though tauopathy progression continues. Monotherapy with steroids (A), plasma exchange (B), or rituximab (C) alone has shown minimal efficacy. Trazodone (E) cannot restore lost REM sleep architecture in this neurodegenerative disorder.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\": Validity label: V (Valid). Verdict on keyed answer: Correct best. Key stem clues: progressive insomnia, dysautonomia, bulbar dysfunction, gait instability; polysomnography shows complete loss of REM sleep; positive anti-IgLON5 antibodies in serum and CSF. These findings define anti-IgLON5 disease, a tauopathy-mediated autoimmune disorder. The question asks for a therapeutic strategy with demonstrated modest symptomatic benefit. Main logical issue: None. The stem provides sufficient detail to identify the disease and the need for immunotherapy. Main medical accuracy issue: None. Current literature supports that combined immunotherapy (steroids, IVIG, rituximab) yields modest benefit, whereas monotherapy is largely ineffective; trazodone does not restore REM sleep architecture. Minimal fix: None required.\",\"logical_false_reason\":\"T\",\"logical_validity\":true,\"medical_accuracy_score\":\"5\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": ": Validity label: V (Valid). Verdict on keyed answer: Correct best. Key stem clues: progressive insomnia, dysautonomia, bulbar dysfunction, gait instability; polysomnography shows complete loss of REM sleep; positive anti-IgLON5 antibodies in serum and CSF. These findings define anti-IgLON5 disease, a tauopathy-mediated autoimmune disorder. The question asks for a therapeutic strategy with demonstrated modest symptomatic benefit. Main logical issue: None. The stem provides sufficient detail to identify the disease and the need for immunotherapy. Main medical accuracy issue: None. Current literature supports that combined immunotherapy (steroids, IVIG, rituximab) yields modest benefit, whereas monotherapy is largely ineffective; trazodone does not restore REM sleep architecture. Minimal fix: None required.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-008", "question": "A 28-year-old phenotypic female with 46,XY karyotype and complete androgen insensitivity syndrome (CAIS) due to a null androgen receptor mutation presents with hypertension (BP 165/100 mmHg) and hypokalemia (K+ 2.8 mEq/L). Plasma renin is suppressed (<0.5 ng/mL/hr) and aldosterone is elevated (35 ng/dL). Which pharmacologic agent specifically targets the underlying mineralocorticoid excess in this syndrome?", "options": ["Eplerenone 50 mg twice daily", "Spironolactone 100 mg twice daily", "Amiloride 10 mg twice daily", "Dexamethasone 0.5 mg nightly", "Finasteride 5 mg daily"], "answer": "B", "answer_index": 1, "explanation": "In CAIS, non-aromatized androgens directly activate mineralocorticoid receptors, causing hypertension. Spironolactone (B) antagonizes this effect while also blocking residual androgen receptor activity. Eplerenone (A) is less effective at the androgen-mediated mineralocorticoid effect. Amiloride (C) treats symptoms but not the mechanism. Dexamethasone (D) suppresses ACTH but not peripheral androgen production. Finasteride (E) blocks 5-alpha-reductase, irrelevant in CAIS with absent receptor function.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable; both spironolactone and eplerenone are mineralocorticoid receptor antagonists that target the elevated aldosterone. The stem does not provide any discriminating factor to prefer one over the other. The explanation’s claim that eplerenone is less effective at “androgen‑mediated” MR activation is unsupported and irrelevant in CAIS. Key stem clues: hypertension, hypokalemia, suppressed renin, elevated aldosterone—classic primary hyperaldosteronism; CAIS is irrelevant to the mineralocorticoid excess. Main logical issue: Two options (A and B) are equally plausible, making the item ambiguous. Main medical accuracy issue: The premise that CAIS causes mineralocorticoid excess via direct androgen activation of MR is not recognized; the explanation misstates the mechanism and the role of spironolactone’s antiandrogenic activity. Minimal fix: Remove the CAIS background and ask which drug is the preferred mineralocorticoid receptor antagonist for primary hyperaldosteronism; if the test wants the non‑selective agent, add a clue such as “patient also has hirsutism requiring antiandrogenic effect” or specify “selective MR antagonist preferred” to differentiate A vs B.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable; both spironolactone and eplerenone are mineralocorticoid receptor antagonists that target the elevated aldosterone. The stem does not provide any discriminating factor to prefer one over the other. The explanation’s claim that eplerenone is less effective at “androgen‑mediated” MR activation is unsupported and irrelevant in CAIS. Key stem clues: hypertension, hypokalemia, suppressed renin, elevated aldosterone—classic primary hyperaldosteronism; CAIS is irrelevant to the mineralocorticoid excess. Main logical issue: Two options (A and B) are equally plausible, making the item ambiguous. Main medical accuracy issue: The premise that CAIS causes mineralocorticoid excess via direct androgen activation of MR is not recognized; the explanation misstates the mechanism and the role of spironolactone’s antiandrogenic activity. Minimal fix: Remove the CAIS background and ask which drug is the preferred mineralocorticoid receptor antagonist for primary hyperaldosteronism; if the test wants the non‑selective agent, add a clue such as “patient also has hirsutism requiring antiandrogenic effect” or specify “selective MR antagonist preferred” to differentiate A vs B.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-009", "question": "A 48-year-old woman with systemic sclerosis presents with NYHA class IV dyspnea. Right heart catheterization: mPAP 52 mmHg, PAWP 6 mmHg, PVR 11 WU. Lung biopsy shows diffuse capillary proliferation within alveolar septa without cellular atypia. She fails to respond to epoprostenol and macitentan. Which intervention is associated with the greatest 5-year survival in this rare WHO Group 1' pulmonary hypertension subset?", "options": ["Switch to inhaled treprostinil 54 μg four times daily", "Add selexipag 1600 μg twice daily", "Initiate combination immunosuppression with cyclophosphamide", "Refer for bilateral lung transplantation", "Perform balloon pulmonary angioplasty"], "answer": "D", "answer_index": 3, "explanation": "Pulmonary capillary hemangiomatosis (PCH) is refractory to all PAH-targeted therapies (A, B) and immunosuppression (C). Balloon angioplasty (E) is contraindicated due to diffuse microvascular disease. Bilateral lung transplantation (D) offers the only survival benefit, with 5-year survival approaching 60% in selected patients, far exceeding the <20% survival on medical therapy alone.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. Verdict: Correct best answer. The stem provides a classic presentation of pulmonary capillary hemangiomatosis (PCH) – a rare WHO Group 1' PH with diffuse capillary proliferation on biopsy, severe pre‑capillary hemodynamics (mPAP 52 mmHg, PAWP 6 mmHg, PVR 11 WU) and failure of epoprostenol and macitentan. These clues uniquely point to a disease that is refractory to all PAH‑targeted drugs (inhaled treprostinil, selexipag) and to immunosuppression (cyclophosphamide). Balloon pulmonary angioplasty is contraindicated in diffuse microvascular disease. Bilateral lung transplantation is the only intervention shown to confer a survival benefit, with reported 5‑year survival ≈60 % in selected patients, far exceeding the <20 % survival on medical therapy. No other option offers a plausible survival advantage. The item is internally consistent, discriminates well, and the key matches the accepted standard of care. Minor improvement: explicitly state ‘refractory to all PAH‑targeted therapies’ in the stem to remove any ambiguity for examinees.\",\"logical_false_reason\":\"T\",\"logical_validity\":true,\"medical_accuracy_score\":\"5\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem provides a classic presentation of pulmonary capillary hemangiomatosis (PCH) – a rare WHO Group 1' PH with diffuse capillary proliferation on biopsy, severe pre‑capillary hemodynamics (mPAP 52 mmHg, PAWP 6 mmHg, PVR 11 WU) and failure of epoprostenol and macitentan. These clues uniquely point to a disease that is refractory to all PAH‑targeted drugs (inhaled treprostinil, selexipag) and to immunosuppression (cyclophosphamide). Balloon pulmonary angioplasty is contraindicated in diffuse microvascular disease. Bilateral lung transplantation is the only intervention shown to confer a survival benefit, with reported 5‑year survival ≈60 % in selected patients, far exceeding the <20 % survival on medical therapy. No other option offers a plausible survival advantage. The item is internally consistent, discriminates well, and the key matches the accepted standard of care. Minor improvement: explicitly state ‘refractory to all PAH‑targeted therapies’ in the stem to remove any ambiguity for examinees.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-010", "question": "A 62-year-old man with chronic type B aortic dissection (diagnosed 3 years ago) presents with massive hemoptysis. CT angiography shows a 7 cm ulcer-like projection in the descending thoracic aorta with active contrast extravasation into the left lower lobe bronchus. He is hypotensive (BP 85/50 mmHg). Which immediate management strategy has the lowest mortality in this aortobronchial fistula complication?", "options": ["Emergent thoracotomy with open surgical repair", "Thoracic endovascular aortic repair (TEVAR) with left subclavian coverage", "TEVAR with adjunctive left subclavian artery revascularization", "Balloon tamponade of the aortic true lumen", "Massive transfusion protocol only"], "answer": "C", "answer_index": 2, "explanation": "Aortobronchial fistula requires emergent TEVAR to seal the rupture. Adjunctive left subclavian revascularization (C) prevents spinal ischemia and reduces perioperative stroke risk compared to coverage alone (B). Open repair (A) carries >80% mortality in this setting. Balloon tamponade (D) is a temporary bridge only. Transfusion alone (E) is futile without definitive hemorrhage control.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V (Valid). Verdict: Correct best answer. Key stem clues: chronic type B aortic dissection, massive hemoptysis, CT showing 7 cm ulcer‑like projection with active contrast extravasation into the left lower‑lobe bronchus, hypotension (85/50 mmHg). These define a ruptured aortobronchial fistula requiring emergent hemorrhage control. TEVAR is the definitive therapy; the choice between LSA coverage alone (B) versus coverage plus revascularization (C) hinges on the known increased risk of spinal cord ischemia and stroke when the LSA is covered without revascularization. Current guidelines and outcome data favor revascularization when feasible, giving C the lowest mortality in this emergent setting. Open repair (A) carries >80 % mortality; balloon tamponade (D) and transfusion alone (E) are only temporizing or futile. No internal contradictions; all distractors are plausible but inferior. Minimal fix: None required; the item is clear and unambiguous. If desired, explicitly state that the ulcer involves the LSA origin to remove any assumption.\",\n  \"medical_accuracy_score\":   \t\"4\",\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V (Valid). Verdict: Correct best answer. Key stem clues: chronic type B aortic dissection, massive hemoptysis, CT showing 7 cm ulcer‑like projection with active contrast extravasation into the left lower‑lobe bronchus, hypotension (85/50 mmHg). These define a ruptured aortobronchial fistula requiring emergent hemorrhage control. TEVAR is the definitive therapy; the choice between LSA coverage alone (B) versus coverage plus revascularization (C) hinges on the known increased risk of spinal cord ischemia and stroke when the LSA is covered without revascularization. Current guidelines and outcome data favor revascularization when feasible, giving C the lowest mortality in this emergent setting. Open repair (A) carries >80 % mortality; balloon tamponade (D) and transfusion alone (E) are only temporizing or futile. No internal contradictions; all distractors are plausible but inferior. Minimal fix: None required; the item is clear and unambiguous. If desired, explicitly state that the ulcer involves the LSA origin to remove any assumption.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}]